These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37994884)

  • 1. [Recognan (citicoline) efficacy and safety in cognitive impairment correction of various nosological forms].
    Shavlovskaya OA; Bokova IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(11):22-28. PubMed ID: 37994884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology].
    Mashin VV; Belova LA; Bakhtogarimov IR; Bergelson TM; Sharafutdinova RR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(8):39-43. PubMed ID: 28884715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of the use of the drug recognan (citicoline) on the state of higher mental functions in patients with mild cognitive impairment].
    Nemkova SA; Semenov DV; Petrova EA; Zavadenko NN; Vozvyshaeva MY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(9):51-57. PubMed ID: 34693689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current treatment options for autonomic, cognitive and emotional disorders in patients with asthenic syndrome treated with recognan (citicoline)].
    Nemkova SA; Semenov DV; Petrova EA; Savchenko DV; Zavadenko NN; Vozvyshaeva MY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(7):27-34. PubMed ID: 31464286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The influence of the drug recognan (citicoline) on neurodynamic characteristics of mental activity in patients with mild cognitive impairment].
    Nemkova SA; Semenov DV; Zavadenko NN; Vozvyshaeva MY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(1):43-46. PubMed ID: 33580760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy of recognan in the early stage of ischemic stroke].
    Mashin VV; Belova LA; Dudikov EM; Bergelson TM; Lankov VA; Zakuraeva KA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):44-48. PubMed ID: 29171488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A multicenter observation study of the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in chronic cerebrovascular pathology].
    Belova LA; Mashin VV; Dudikov EM; Belov DV; Krupennikov AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2):35-38. PubMed ID: 30874524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Features of positive personality phenomena in patients with mild cognitive impairment and asthenic syndrome treated with recognan (citicoline)].
    Nemkova SA; Semenov DV; Zavadenko NN; Vozvyshaeva MY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(1):44-50. PubMed ID: 32105268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cognitive and emotional disorders in university students and teachers: the possibility of treatment with recognan (citicoline)].
    Nemkova SA; Semenov DV; Petrova EA; Savchenko DV; Zavadenko NN; Vozvyshaeva MY; Kanishcheva AS; Ralleva AV; Logvinova EM; Tsvetkov DA; Charikova EV; Romanenko NI; Zagaryan DA; Boldyrev VG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(12):11-18. PubMed ID: 30698554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study.
    Cotroneo AM; Castagna A; Putignano S; Lacava R; Fantò F; Monteleone F; Rocca F; Malara A; Gareri P
    Clin Interv Aging; 2013; 8():131-7. PubMed ID: 23403474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment.
    Alvarez-Sabín J; Ortega G; Jacas C; Santamarina E; Maisterra O; Ribo M; Molina C; Quintana M; Román GC
    Cerebrovasc Dis; 2013; 35(2):146-54. PubMed ID: 23406981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.
    Fioravanti M; Yanagi M
    Cochrane Database Syst Rev; 2005 Apr; (2):CD000269. PubMed ID: 15846601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impairments of cognitive control in patients with somatoform disorders and their treatment].
    Chutko LS; Surushkina SY; Yakovenko EA; Anisimova TI; Karpovskaya EB; Vasilenko VV; Didur MD; Volov MB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(4):32-37. PubMed ID: 31156219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Citicoline: pharmacological and clinical review, 2006 update.
    Secades JJ; Lorenzo JL
    Methods Find Exp Clin Pharmacol; 2006 Sep; 28 Suppl B():1-56. PubMed ID: 17171187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The assessment of the efficacy of citicoline in the early and recovery stages of stroke].
    Shavlovskaya OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):93-97. PubMed ID: 28635796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.
    Fioravanti M; Yanagi M
    Cochrane Database Syst Rev; 2000; (4):CD000269. PubMed ID: 11034681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature.
    Conant R; Schauss AG
    Altern Med Rev; 2004 Mar; 9(1):17-31. PubMed ID: 15005642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.
    Fioravanti M; Yanagi M
    Cochrane Database Syst Rev; 2000; (2):CD000269. PubMed ID: 10796523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives.
    Gareri P; Castagna A; Cotroneo AM; Putignano S; De Sarro G; Bruni AC
    Clin Interv Aging; 2015; 10():1421-9. PubMed ID: 26366063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ceraxon (citicoline) in the treatment of the mild cognitive impairment syndrome].
    Gavrilova SI; Fedorova IaB; Gantman ; Kalyn IaB; Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):16-20. PubMed ID: 22433803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.